TheEdgeResearch
Home / Stocks / GENO.ST

Genovis AB (GENO.ST)

STO Healthcare Biotechnology
$18.98 ▲ +2.59%
Market Cap
$1.25B
Sector
Healthcare
Industry
Biotechnology
Beta
1.73
52-Wk Range
15.64-24.5
CEO
Fredrik Olsson
Country
SE
Currency
SEK

Genovis AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Kävlinge, SN, SE. The stock last traded at $18.98, up 2.59% on the session, giving a market capitalisation of $1.25B. Its beta of 1.73 implies it has historically moved more than the broad market.

Company profile
Exchange
Stockholm Stock Exchange
Employees
42
IPO date
2017-04-28
Headquarters
Kävlinge, SN, SE
About Genovis AB

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Comparable companies

Genovis AB is most often compared with the following Healthcare names:

BICO.STCANTA.STDMYD-B.STITECH.STONCO.STOSSD.STPAX.STSTIL.STSYNACT.STXSPRAY.ST
More research on GENO.ST
GENO.ST technical analysis GENO.ST TheEdge Score Compare against peers
Open full interactive analysis & DCF →